Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.67 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13443055 | 0.87 | HCRTR1 (0.57) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL12024786 | 0.82 | HCRTR1 (0.54) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3624972 | 0.82 | HCRTR1 (0.59) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3624251 | 0.81 | HCRTR1 (0.77) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3624546 | 0.81 | HCRTR1 (0.77) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3621447 | 0.81 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3622216 | 0.81 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL30731018 | 0.79 | HPGDS (0.56) | HTTKMT2A | |
| SCHEMBL3617294 | 0.79 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL12024779 | 0.79 | HPGDS (0.55) | HTTKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR1 2/4885HCRTR2 1/4885HTR1A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.